文献速递关节外科创伤骨科

髋膝关节假体周围感染:一期、1.5期与二期翻修的网络Meta分析

One-, 1.5-, or Two-Stage Revision for Periprosthetic Hip and Knee Joint Infection? A Network Meta-Analysis Comparing Revision Strategies.
PubMed 文献 · J Arthroplasty · 2026-09-07

该研究通过系统综述与贝叶斯网络Meta分析,比较了慢性髋膝关节假体周围感染一期、1.5期与二期翻修策略的临床结局,纳入54项研究共10055例患者。结果显示1.5期翻修感染相关结局最优但无菌性松动风险显著升高,一期翻修总体并发症较少,二期翻修感染相关结局较差但松动风险最低。

要点

  • 1.5期翻修感染控制成功率最高,但无菌性松动风险显著增加。
  • 一期翻修再感染与再手术风险低于二期,总体并发症也更少。
  • 证据以观察性研究为主,存在适应证混杂,结论需谨慎解读。

核心结论

  • 1.5期翻修与最有利的感染相关结局相关,但无菌性松动风险更高。
  • 一期翻修结果居中,二期翻修感染相关结局较差但松动风险最低。
  • 证据主要为观察性研究且受适应证混杂影响,这些关联应谨慎解读。

研究设计与样本

  • 系统综述与贝叶斯网络Meta分析,检索数据库截至2025年10月。
  • 纳入评估髋膝关节慢性假体周围感染一期、1.5期与二期翻修的随机对照试验和比较性队列研究。
  • 慢性假体周围感染按MSIS/ICM标准定义,排除急性术后和血源性感染。
  • 主网络合并分析髋与膝翻修,并预设髋-only和膝-only亚组网络单独报告。
  • 共纳入54项研究、10055例患者。

主要发现

  • 与二期翻修相比,一期翻修再感染几率显著更低(OR=0.84,95%CrI 0.72至0.99)。
  • 与二期翻修相比,1.5期翻修再感染几率显著更低(OR=0.58,95%CrI 0.37至0.89)。
  • 与二期翻修相比,一期翻修再手术几率显著更低(OR=0.79,95%CrI 0.63至0.99)。
  • 与二期翻修相比,1.5期翻修再手术几率显著更低(OR=0.20,95%CrI 0.05至0.82)。
  • 1.5期翻修感染控制成功率显著更高(OR=1.64,95%CrI 1.07至2.51),但无菌性松动风险显著增加(OR=4.80,95%CrI 1.57至20.79);一期翻修总体并发症更少(OR=0.64,95%CrI 0.48至0.86)。

关键数值与推荐

  • 慢性假体周围感染定义采用MSIS/ICM标准,排除急性术后和血源性感染。
  • 再感染:一期翻修OR=0.84(95%CrI 0.72至0.99),1.5期翻修OR=0.58(95%CrI 0.37至0.89),均对比二期翻修。
  • 再手术:一期翻修OR=0.79(95%CrI 0.63至0.99),1.5期翻修OR=0.20(95%CrI 0.05至0.82),均对比二期翻修。
  • 感染控制成功:1.5期翻修OR=1.64(95%CrI 1.07至2.51);总体并发症:一期翻修OR=0.64(95%CrI 0.48至0.86);无菌性松动:1.5期翻修OR=4.80(95%CrI 1.57至20.79)。

临床怎么用

  • 选择翻修策略时需权衡感染控制与无菌性松动风险,1.5期翻修感染相关结局更优但松动风险更高。
  • 一期翻修再感染、再手术和总体并发症风险低于二期翻修,可作为部分患者的可选策略。
  • 因证据以观察性研究为主且存在适应证混杂,应结合患者具体情况谨慎应用上述关联。

局限性

  • 证据 largely 为观察性研究,受适应证混杂影响。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Periprosthetic joint infection (PJI) remains a devastating complication following total hip and knee arthroplasty. Revision strategies for chronic PJI include one-, 1.5-, and two-stage revision procedures. This study compared clinical outcomes of these revision strategies using a network meta-analytic approach. METHODS: A systematic review and Bayesian network meta-analysis were conducted. Databases were searched through October 2025. Randomized controlled trials and comparative cohort studies evaluating one-, 1.5-, and two-stage revision procedures for hip and knee chronic PJI were included. Chronic PJI was defined by Musculoskeletal Infection Society/International Consensus Meeting (MSIS/ICM) criteria, excluding acute postoperative and hematogenous infections. In the primary network, hip and knee revisions were analyzed together, with pre-specified hip-only and knee-only subgroup networks reported separately. There were 54 studies (10,055 patients) eligible for inclusion. RESULTS: Compared with two-stage revision, both one- and 1.5-stage revisions were associated with significantly lower odds of reinfection (odds ratio (OR) = 0.84, 95% credible interval (CrI) 0.72 to 0.99 and OR = 0.58, 95% CrI 0.37 to 0.89, respectively) and reoperation (OR = 0.79, 95% CrI 0.63 to 0.99 and OR = 0.20, 95% CrI 0.05 to 0.82, respectively). The 1.5-stage strategy demonstrated significantly higher infection control success (OR = 1.64, 95% CrI 1.07 to 2.51). The one-stage revision was associated with fewer overall complications (OR = 0.64, 95% CrI 0.48 to 0.86). The 1.5-stage strategy showed a significantly increased risk of aseptic loosening (OR = 4.80, 95% CrI 1.57 to 20.79), while two-stage revision performed best. CONCLUSION: The 1.5-stage revision was associated with the most favorable infection-related outcomes, but a higher risk of aseptic loosening. The one-stage revision showed intermediate results, while the two-stage revision performed less favorably but had the lowest loosening risk. Because the evidence is largely observational and subject to confounding by indication, these associations should be interpreted cautiously.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Selim A, Ibrahim A, Saeed A, et al. One-, 1.5-, or Two-Stage Revision for Periprosthetic Hip and Knee Joint Infection? A Network Meta-Analysis Comparing Revision Strategies. J Arthroplasty. 2026. PMID: 42705360. doi:10.1016/j.arth.2026.08.069

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。